RARE

AI Memo

Ultragenyx Pharmaceutical

As of 2026-09-04/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Unresolved gene-therapy regulatory read-through • 2026-12-03

Base target: $17 / p=45% prob

Biggest risk

The GTX-102 failure removes a major pipeline value driver, while management has not yet decided the program's disposition and plans significant expense reductions. Regulatory status for the other gene-therapy programs is incomplete, and insider activity shows recent open-market sales by the CFO and a director. [#SEC-8K-2026-09-02] [#SEC-FORM4-2026-08-04] [#SEC-FORM4-2026-05-18]

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Ultragenyx retains a commercial revenue base, reaffirmed 2026 guidance, and a potential path to profitability in 2027. Favorable remaining regulatory read-through and disciplined expense reductions could stabilize the shares. [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

high

As of

2026-09-04

Base target

$17

p=45%

Bull target

$26

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Aspire Phase 3 failure resets pipeline value
Commercial base and profitability execution
Ultragenyx retains a commercial revenue base, reaffirmed 2026 guidance, and a potential path to profitability in 2027.

BearKey bullets

2026 revenue guidance excludes potential new product launches, increasing sensitivity to regulatory timing.
[#SEC-8K-2026-08-04]
DTX-401 and UX-111 regulatory decision status is incomplete in the packet.

WatchKey bullets

Unresolved gene-therapy regulatory read-through

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $17 (p=45%)

Target spread vs base: +51% / -47%

Scenario probabilities

Bull Target: $26 (p=25%)Base Target: $17 (p=45%)Bear Target: $9 (p=30%)

Commentary

News tone is sharply negative after the GTX-102 failure, with high headline attention and an approximately 45% reported premarket decline; see [Ultragenyx shares fall after Phase 3 Aspire study misses primary endpoint](https://finance.yahoo.com/healthcare/articles/ultragenyx-shares-fall-phase-3-110050243.html). Social coverage, options data, short interest, employee sentiment, and post-print analyst revisions are unavailable or unvalidated, so the setup remains a cautious monitoring view.

As of 2026-09-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Aspire Phase 3 failure resets pipeline value
Commercial base and profitability execution

Scenarios

Bull Target (Scenario probability)

$26 / p=25% prob

Base Target (Scenario probability)

$17 / p=45% prob

Bear Target (Scenario probability)

$9 / p=30% prob

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.82

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-03
Unresolved gene-therapy regulatory read-through
The August earnings exhibit identified two second-half 2026 PDUFA catalysts, including DTX-401's August 23 action date, but the packet does not confirm the decision status or provide UX-111's exact date. This remains a monitoring catalyst rather than a high-conviction upside trigger. [#SEC-8K-2026-08-04]
Prob 40.00% • Move 25.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Aspire Phase 3 failure resets pipeline value
2026-09-02
Ultragenyx reported that GTX-102 missed both the Bayley-4 cognitive primary endpoint and MDRI key secondary endpoint; program disposition is under review and significant expense reductions are planned. Secondary coverage reported an approximately 45% premarket decline, so much of the initial shock appears priced in. [#SEC-8K-2026-09-02]
Prob 100% • Move -15% • Priced-in 85%

Long-term Catalysts

Months to a year

Commercial base and profitability execution
2027-09-04
Q2 revenue was $214 million, described as the company's highest quarterly revenue, with 2026 revenue guidance reaffirmed at $730-$760 million excluding potential new launches and profitability still targeted for 2027. Execution and cost reductions could provide support, but the failed trial raises uncertainty around the broader portfolio. [#SEC-8K-2026-08-04] [#SEC-8K-2026-09-02]
Prob 55% • Move 25% • Priced-in 35%

Risks

2026 revenue guidance excludes potential new product launches, increasing sensitivity to regulatory timing. [#SEC-8K-2026-08-04]
DTX-401 and UX-111 regulatory decision status is incomplete in the packet.
GTX-102 failed both pivotal efficacy endpoints, with program disposition undecided. [#SEC-8K-2026-09-02]
Peer comparability and analyst-target breadth are weak, limiting valuation confidence.
Recent CFO and director open-market sales are a caution signal, though they do not establish operating deterioration. [#SEC-FORM4-2026-08-04] [#SEC-FORM4-2026-05-18]
Significant expense reductions could disrupt pipeline development or commercial execution. [#SEC-8K-2026-09-02]

Peers

Symbol	Summary
BCRX	Same-sector, similar-market-cap screening peer at approximately $2.54 billion; operating and indication comparability is not validated in the packet.
KOD	Same-sector, similar-market-cap screening peer at approximately $2.58 billion; use only as loose valuation/risk context because direct business comparability is unconfirmed.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-04

Loading AI feed…

Symbol

Summary

BCRX

Same-sector, similar-market-cap screening peer at approximately $2.54 billion; operating and indication comparability is not validated in the packet.

KOD

Same-sector, similar-market-cap screening peer at approximately $2.58 billion; use only as loose valuation/risk context because direct business comparability is unconfirmed.